Browsing by Author "Aslan, Kubra"

Now showing 1 - 2 of 2

Alantolactone Ameliorates Graft Versus Host Disease in Mice
(Elsevier, 2024) Odabas, Gul Pelin; Aslan, Kubra; Suna, Pinar Alisan; Kendirli, Perihan Kader; Erdem, Serife; Cakir, Mustafa; Unal, Ekrem
The anti-inflammatory and immunosuppressive drugs which are used in the treatment of Graft-versus-Host Disease (GVHD) have limited effects in controlling the severity of the disease. In this study, we aimed to investigate the prophylactic effect of Alantolactone (ALT) in a murine model of experimental GVHD. The study included 4 BALB/c groups as hosts: Naive (n = 7), Control GVHD (n = 16), ALT-GVHD (n = 16), and Syngeneic transplantation (n = 10). Busulfan (20 mg/kg/day) for 4 days followed by cyclophosphamide (100 mg/kg/day) were administered for conditioning. Allogeneic transplantation was performed with cells collected from mismatched female C57BL/6, and GVHD development was monitored by histological and flow cytometric assays. Additionally, liver biopsies were taken from GVHD patient volunteers between ages 2-18 (n = 4) and non-GVHD patients between ages 2-50 (n = 5) and cultured ex vivo with ALT, and the supernatants were used for ELISA. ALT significantly ameliorated histopathological scores of the GVHD and improved GVHD clinical scores. CD8+ T cells were shown to be reduced after ALT treatment. More importantly, ALT treatment skewed T cells to a more naive phenotype (CD62L+ CD44-). ALT did not alter Treg cell number or frequency. ALT treatment appears to suppress myeloid cell lineage (CD11c+). Consistent with reduced myeloid lineage, liver and small intestine levels of GM-CSF were reduced in ALT-treated mice. IL-6 gene expression was significantly reduced in the intestinal tissue. Ex vivo ALT-treated liver biopsy samples from GVHD patients showed a trend of decrease in proinflammatory cytokines but there was no statistical significance. Collectively, the data indicated that ALT may have immunomodulatory actions in a preclinical murine GVHD model.
Enzyme Inhibition Properties of Calendula Officinalis, Matricaria Chamomilla, and Anthemis Pseudocotula: Kinetics and Molecular Docking Studies
(Acg Publications, 2025) Aslan, Kubra; Kiziltas, Hatice; Guven, Leyla; Karagecili, Hasan; Arslan, Dogan; Gulcin, Ilhami
This study determined the enzyme inhibition potential of three species (Calendula officinalis, Matricaria chamomilla, and Anthemis pseudocotula) from the Asteraceae family through in silico, followed by in vitro studies. Quinic acid, fumaric acid, gallic acid, chlorogenic acid, vanillic acid, quercetin, apigenin, and isorhamnetin were determined by LC-MS/MS in all of the species. Metabolic enzymes are essential catalysts regulating biochemical reactions within living organisms, facilitating energy production, detoxification, and biosynthesis. These enzymes play a crucial role in maintaining cellular homeostasis and are tightly regulated to ensure optimal metabolic function. High docking scores were also obtained for butyrylcholinesterase (BChE), alpha-glycosidase, alpha-amylase, and human carbonic anhydrase I and II enzymes (hCA I and hCA II). Among the extracts, Anthemis pseudocotula was concluded to be the best inhibitor for the enzymes, which was further determined by in vitro enzyme inhibition tests. Besides, it was concluded that all extracts showed anti-cholinergic, anti-diabetic, and anti-glaucoma properties. This is the first study determining the enzyme inhibition property of Anthemis pseudocotula and the three species' hCA I and hCA II inhibition activities.